Six new Cu(I) complexes with pincer N-heterocyclic carbene (NHC) ligands of the type 2,6-bis(3-alkylimidazol-2-ylidene)pyridine, I(R), and 2,6-bis(3-alkylimidazol-2-ylidene)methylpyridine, I(R), where R = Me, Et, and Pr have been synthesized using Cu precursors and bis(imidazolium) salts. All of these compounds, namely, [Cu(IMe)](PF), 1; [Cu(IEt)](PF), 2; [Cu(IPr)](PF), 3; [Cu(IMe)](PF), 4; [Cu(IEt)](PF), 5; and [Cu(IPr)](PF), 6, have been characterized by H andC NMR spectroscopies, elemental analysis, solution conductivity, and electrochemical studies. Single crystal X-ray structures were obtained for all complexes except 1. The crystallographic data reveal a binuclear structure containing two Cu atoms at a close distance, 2.622-2.811 Å for all the complexes except 5, which shows a unique mononuclear structure. Spatial syn arrangement of ethyl groups and extensive π-π stacking in the solid state accounts for the mononuclear structure of complex 5. A pseudolinear coordination geometry about metal centers consisting of two Cu-carbene bonds, as well as weak Cu-pyridine interactions, exist among all the complexes independent of their ligand. Solution-state conductivity data reveal a dominant 1:2 electrolyte behavior for 1-3 but 1:1 electrolyte for 4-6, consistent with the sustainable binuclear structure in solutions of Cu(I)-I(R) complexes. Cyclic voltammetry and differential pulse voltammetry studies reveal an irreversible and two quasi-reversible peaks for the one-electron oxidation of solvent-bound and solvent-free binuclear and mononuclear Cu-NHC species in complexes 1-3. In contrast, the reversible Cu(II)/Cu(I) couples of 4-6 at potentials close to that of complexes with tripodal polydentate NHC scaffolds indicate the electronic and structural flexibility of I(R) ligands to accommodate both Cu(I) and Cu(II) ions.

Vanadium compounds have been set in various fields as anticancer, anti-diabetic, anti-parasitic, anti-viral, and anti-bacterial agents. This study reports the synthesis and structural characterization of oxidovanadium(IV)-based imidazole drug complexes by the elemental analyzer, molar conductance, magnetic moment, spectroscopic techniques, as well as thermal analysis. The obtained geometries were studied theoretically using density functional theory (DFT) under the B3LYP level. The DNA-binding nature of the ligands and their synthesized complexes has been studied by the electronic absorption titrations method. The biological studies were carried with in-vivo assays and the molecular docking method. The EPR spectra asserted the geometry around the vanadium center to be a square pyramid for metal complexes. The geometries have been confirmed using DFT under the B3LYP level. Moreover, the quantum parameters proposed promising bioactivity of the oxidovanadium(IV) complexes. The results of the DNA-binding revealed that the investigated complexes bind to DNA via non-covalent mode, and the intrinsic binding constant (Kb) value for the [VO(SO4)(MNZ)2] H2O complex was promising, which was 2.0 × 106 M−1. Additionally, the cytotoxic activity of the synthesized complexes exhibited good inhibition toward both hepatocellular carcinoma (HepG-2) and human breast cancer (HCF-7) cell lines. The results of molecular docking displayed good correlations with experimental cytotoxicity findings. Therefore, these findings suggest that our synthesized complexes can be introduced as effective anticancer agents.

Over the last two decades, N-heterocyclic carbene (NHC)–copper catalysts have received considerable attention in organic synthesis. Despite the popularity of copper complexes containing monodentate NHC ligands and recent development of poly(NHC) platforms, their application in C–C and C–heteroatom cross-coupling reactions has been limited. Recently, we reported an air-assisted Sonogashira-type cross-coupling catalyzed by well-defined cationic copper-pincer bis(NHC) complexes. Herein, we report the application of these complexes in Ullmann-type C–X (X = N, O) coupling of azoles and phenols with aryl halides in a relatively short reaction time. In contrast to other well-defined copper(I) catalysts that require an inert atmosphere for an efficient C–X coupling, the employed Cu(I)-pincer bis(NHC) complexes provide good to excellent yields in air. The air-assisted reactivity, unlike that in the Sonogashira reaction, is also affected by the base employed and the reaction time. With Cs2CO3 and K2CO3, the oxygen-generated catalyst is more reactive than the catalyst formed under argon in a short reaction time (12 h). However, the difference in reactivity is compromised after a 24 h reaction with K2CO3. The efficient pincer Cu-NHC/O2/Cs2CO3 system provides great to excellent cross-coupling yields for electronically diverse aryl iodides and imidazole derivatives. The catalyst scope is controlled by a balance between nucleophilicity, coordinating ability, and the steric hindrance of aryl halides and N-/O-nucleophiles.

No abstract

Four new drug-based oxidovanadium (IV) complexes were synthesized and characterized by various spectral techniques, including molar conductance, magnetic measurements, and thermogravimetric analysis. Moreover, optimal structures geometry for all syntheses was obtained by the Gaussian09 program via the DFT/B3LYP method and showed that all of the metal complexes adopted a square-pyramidal structure. The essential parameters, electrophilicity (ω) value and expression for the maximum charge that an electrophile molecule may accept (ΔNmax) showed the practical biological potency of [VO(CTZ)2] 2H2O. The complexes were also evaluated for their propensity to bind to DNA through UV–vis absorption titration. The result revealed a high binding ability of the [VO(CTZ)2] 2H2O complex with Kb = 1.40 × 10⁶ M−1. Furthermore, molecular docking was carried out to study the behavior of the VO (II) complexes towards colon cancer cell (3IG7) protein. A quantitative structure–activity relationship (QSAR) study was also implemented for the newly synthesized compounds. The results of validation indicate that the generated QSAR model possessed a high predictive power (R2 = 0.97). Within the investigated series, the [VO(CTZ)2] 2H2O complex showed the greatest potential the most selective compound comparing to the stander chemotherapy drug.